What Makes Maze Therapeutics (MAZE) One of the Best Oversold Small-Cap Stocks to Buy [Yahoo! Finance]
Maze Therapeutics, Inc. (MAZE)
Company Research
Source: Yahoo! Finance
As of the April 24 closing, the consensus sentiment around the stock was strongly bullish. It received Buy ratings from all 12 analysts who provided coverage. Moreover, it offers almost 150% upside potential, based on a median 1-year price target of $64.45, making it one of the most attractive small-cap picks. Pressmaster/Shutterstock.com The bullish views are also backed by the company's latest trial outcomes. Back on March 25, Maze Therapeutics Inc. (NASDAQ:MAZE) revealed encouraging results from the Phase 2 HORIZON trial on MZE829, an oral drug inhibiting APOL1, in treating a range of APOL1-induced kidney diseases. 12 weeks of administration of the drug brought about a 35.6% reduction in the mean value of albumin/creatinine ratio in broad AMKD patients, where 50% of patients had a reduction exceeding 30%. Patients diagnosed with FSGS condition recorded a reduction in mean value by 61.8%, while those suffering from non-diabetic AMKD saw a reduction by 48.6%. There were no sev
Show less
Read more
Impact Snapshot
Event Time:
MAZE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MAZE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MAZE alerts
High impacting Maze Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MAZE
News
- Maze Therapeutics Announces $150 Million Registered OfferingGlobeNewswire
- Truist Updates Maze Therapeutics, Inc. (MAZE) Model for Share Count and Warrant Impact [Yahoo! Finance]Yahoo! Finance
- Maze Therapeutics (MAZE) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=MAZE&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "holdMarketBeat
- Maze Therapeutics (MAZE) was given a new $64.00 price target by Truist Financial Corporation.MarketBeat
- Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors. [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
MAZE
Earnings
- 3/25/26 - Beat
MAZE
Sec Filings
- 4/28/26 - Form ARS
- 4/28/26 - Form DEFA14A
- 4/28/26 - Form DEF
- MAZE's page on the SEC website